Critical Review Confirms CBD Works for Refractory Epilepsy in Children
A critical review of 69 articles confirmed CBD's efficacy for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in children, with most side effects mild to moderate and transient.
Quick Facts
What This Study Found
CBD efficacy for treating seizures has been confirmed by RCTs for LGS, Dravet syndrome, and TSC. Side effects are frequent but mostly mild to moderate and transient. There is no global consensus on regulatory approval, but CBD is considered promising with a good safety profile.
Key Numbers
69 articles reviewed; efficacy confirmed for LGS, Dravet, TSC; side effects mostly mild-moderate and transient
How They Did This
Critical literature review of 69 articles from PubMed, Cochrane, and SciELO databases, without date, language, or study design restrictions, covering CBD for refractory epilepsy in pediatric populations.
Why This Research Matters
For families of children with treatment-resistant epilepsy, knowing that CBD has been confirmed effective through rigorous clinical trials provides evidence-based guidance in a landscape full of unproven claims.
The Bigger Picture
While CBD has become the most successful cannabinoid medicine to date, regulatory approaches vary globally. The evidence base continues to support expanding access for children with these specific epilepsy syndromes.
What This Study Doesn't Tell Us
Review focused on published literature which may have publication bias. Long-term safety data in pediatric populations remain limited.
Questions This Raises
- ?Could CBD be effective for other childhood epilepsy syndromes beyond the three approved indications?
- ?What are the long-term neurodevelopmental effects of chronic CBD use in children?
Trust & Context
- Key Stat:
- RCT-confirmed efficacy for 3 epilepsy syndromes
- Evidence Grade:
- Comprehensive review of 69 articles including randomized controlled trials that led to regulatory approvals.
- Study Age:
- Published in 2022
- Original Title:
- Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature.
- Published In:
- Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo, 41, e2021197 (2022)
- Authors:
- Moreira, Gabriela Araujo, Moraes Neto, Roddie, Ribeiro, Ricardo Gullit, Crippa, Ana Chrystina De Souza
- Database ID:
- RTHC-04080
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does CBD work for children with epilepsy?
Yes, for specific conditions. Randomized controlled trials have confirmed CBD reduces seizures in children with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Is CBD safe for children?
This review found side effects are frequent but mostly mild to moderate and temporary. The drug has a "good safety and tolerance profile," though more long-term studies are needed.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04080APA
Moreira, Gabriela Araujo; Moraes Neto, Roddie; Ribeiro, Ricardo Gullit; Crippa, Ana Chrystina De Souza. (2022). Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature.. Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo, 41, e2021197. https://doi.org/10.1590/1984-0462/2023/41/2021197
MLA
Moreira, Gabriela Araujo, et al. "Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature.." Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo, 2022. https://doi.org/10.1590/1984-0462/2023/41/2021197
RethinkTHC
RethinkTHC Research Database. "Cannabidiol for the treatment of refractory epilepsy in chil..." RTHC-04080. Retrieved from https://rethinkthc.com/research/moreira-2022-cannabidiol-for-the-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.